An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 2/1/2019 |
| Start Date: | August 14, 2018 |
| End Date: | March 21, 2019 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, |
| Email: | Clinical.Trials@bms.com |
| Phone: | please email: |
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BMS-986224 in Participants With Varying Degrees of Renal Function
The purpose of this study is to investigate the experimental medication BMS-986224 in
participants with varying levels of renal function.
participants with varying levels of renal function.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- BMI ≥18 and ≤ 35kg/m2
- Systolic blood pressure >100 mmHg
Exclusion Criteria:
- Women of childbearing potential or women who are currently pregnant
- Clinically relevant abnormal medical history, abnormal findings on physical
examination, vital signs, ECG, or laboratory tests at screening that the investigator
judges as likely to interfere with the objectives of the trial or the safety of the
volunteer
- Current or recent (within 3 months of study treatment administration) gastrointestinal
disease that could affect absorption
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
4
sites
5055 South Orange Ave Orlando FL 32909
Orlando, Florida 32806
Orlando, Florida 32806
407-240-7878
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials